Sickle Cell Disease Treatment of Pain Continuing Education
Laid on Table; Companion bill(s) passed, see CS/SB 844 (Ch. 2026-6)
Summary
The bill would require any Florida health professional who is registered with the DEA and authorized to prescribe controlled substances to complete a board‑approved two‑hour continuing‑education course covering opioid prescribing standards, alternatives, non‑pharmacologic therapies, emergency opioid antagonists, and pain treatment for patients with sickle‑cell disease. The course must be taken by Jan 31 2019 and at each license renewal, and failure to complete it could block license renewal. The measure failed, being laid on the table, though a companion bill (CS/SB 844) passed.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HB 353 changes status, plus AI-powered summaries and stage predictions.
Sign up free